Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Distinct fatigue profiles and psychological mechanisms among breast cancer survivors: A latent profile and mediation analysis.

Dusunen adam : Bakirkoy Ruh ve Sinir Hastaliklari Hastanesi yayin organi·2026

Same author

Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician-patient survey.

Scientific reports·2026

Same author

Domain-Level Distribution of Pathogenic BRCA1/2 Somatic Mutations Shows No Evidence of Large Subtype-Specific Enrichment in Breast Cancer: A Three-Cohort Analysis Supporting Broad BRCA Testing.

Genes·2026

Same author

Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

Medicina (Kaunas, Lithuania)·2026

Same author

Real-World Efficacy and Safety of Frontline Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma: A Multicenter Study and Review of the Literature.

Clinical genitourinary cancer·2026

Same author

A survey on the management of chronic myeloid leukemia in chronic phase from the perspectives of both patients and physicians.

Annals of hematology·2026

Search research articles

Related Experiment Video

Updated: Nov 18, 2025

Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation

Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation

Published on: August 8, 2025

IPS-3 Validation in 1012 cases with classical hodgkin lymphoma.

Semra Paydas¹, Sahin Laçin², Mutlu Doğan³

¹Cukurova University Fac of Med Dept of Medical Oncology, Turkey.

Leukemia Research

|February 8, 2021

Summary

The IPS-3 scoring system effectively predicts outcomes for advanced classical Hodgkin Lymphoma (cHL) patients treated with ABVD chemotherapy. This simpler system identifies risk levels, aiding clinical practice.

Keywords:

Hodgkin lymphoma IPS-3 Survival Validation

More Related Videos

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Related Experiment Videos

Last Updated: Nov 18, 2025

Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation

Field-Deployable Lens-Free Imaging Platform for Rapid Label-Free Analysis of Natural Killer Cell Activation

Published on: August 8, 2025

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma

Published on: June 10, 2017

Area of Science:

Hematology
Oncology
Clinical Prognostics

Background:

Classical Hodgkin Lymphoma (cHL) is a significant hematologic malignancy.
Accurate prognostic indicators are crucial for tailoring treatment strategies in advanced cHL.
The International Prognostic Score (IPS) has been used, but simpler alternatives are sought.

Purpose of the Study:

To validate the IPS-3 scoring system as a prognostic tool for advanced cHL.
To compare the prognostic value of IPS-3 with the established IPS-7 system.
To assess the predictive capability of IPS-3 in patients receiving ABVD chemotherapy.

Main Methods:

Retrospective analysis of 1012 advanced cHL patients treated with ABVD.
Univariate and multivariate Cox regression analyses were performed.
Evaluation of individual risk factors and the overall IPS-3 and IPS-7 scores for overall survival (OS) and progression-free survival (PFS).

Main Results:

The IPS-3 system categorized patients into low (50.8%), intermediate (45.8%), and high (3.5%) risk groups.
Age, stage, and hemoglobin were identified as independent significant risk factors for OS and PFS in multivariate analysis.
Gender and albumin were not independent predictors in the Cox regression model.
IPS-3 proved to be a reliable prognostic indicator, comparable to IPS-7 but easier to calculate.

Conclusions:

The IPS-3 scoring system is a validated and practical prognostic tool for advanced cHL patients treated with ABVD.
IPS-3 simplifies risk stratification, facilitating its use in routine clinical practice.
This system aids in predicting survival outcomes and guiding treatment decisions for cHL patients.